Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $23.99
  • 50 Day Moving Average: $21.86
  • 200 Day Moving Average: $14.14
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -57.12
  • P/E Growth: 31.31
  • Market Cap: $N/A
  • Beta: 2.16
Profitability:
  • Net Margins: -16.99%
  • Return on Assets: -5.12%
Debt:
  • Debt-to-Equity Ratio: -11.28%
  • Current Ratio: 3.17%
  • Quick Ratio: 3.15%
Additional Links:
Companies Related to Ariad Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.10)
Consensus Price Target: $16.54 (31.05% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
DateFirmActionRatingPrice TargetDetails
1/11/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$24.00View Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$16.00View Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
1/10/2017Barclays PLCUpgradeUnderweight -> Equal Weight$9.00 -> $24.00View Rating Details
1/10/2017Jefferies Group LLCDowngradeBuy -> Hold$11.00 -> $24.00View Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00View Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageHold$9.50View Rating Details
10/24/2016J P Morgan Chase & CoDowngradeNeutral -> Underweight$9.97 -> $7.00View Rating Details
6/20/2016Royal Bank of CanadaReiterated RatingHoldView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$7.00 -> $5.00View Rating Details
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017        
11/7/2016Q316($0.19)($0.12)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20164($0.21)($0.17)($0.19)
Q4 20164($0.19)($0.16)($0.18)
Q1 20172($0.24)($0.21)($0.23)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.22)($0.22)($0.22)
Q4 20172($0.57)($0.21)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateHeadline
News IconJapan’s Takeda Pharmaceutical Downgraded To ‘A-/A-2’ On Expected Weaker Financials; Outlook Negative (NASDAQ:ARIA)
www.thaipr.net - February 27 at 8:07 AM
News IconNASDAQ:ARIA Investor Notice: Lawsuit in effort to Halt the Takeover of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)
www.groundreport.com - February 24 at 12:36 PM
News IconAnalysts Peer Into Their Crystal Balls For ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA): Where Is It headed? - Winfield Review (NASDAQ:ARIA)
winfieldreview.com - February 23 at 3:37 PM
News IconTracking the Metrics on Shares of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - The Standard (NASDAQ:ARIA)
6milestandard.com - February 22 at 3:38 PM
News IconTakeda completes acquisition of ARIAD Pharmaceuticals (NASDAQ:ARIA)
www.biospectrumasia.com - February 21 at 8:48 AM
reuters.com logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - Reuters (NASDAQ:ARIA)
www.reuters.com - February 18 at 3:34 PM
reuters.com logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals (NASDAQ:ARIA)
www.reuters.com - February 17 at 6:32 PM
marketexclusive.com logoARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:ARIA)
marketexclusive.com - February 17 at 6:32 PM
prnewswire.com logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US (NASDAQ:ARIA)
www.prnewswire.com - February 16 at 8:41 PM
prnewswire.com logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US (NASDAQ:ARIA)
www.prnewswire.com - February 16 at 8:41 PM
streetinsider.com logoTakeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA) (NASDAQ:ARIA)
www.streetinsider.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o (NASDAQ:ARIA)
biz.yahoo.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o (NASDAQ:ARIA)
biz.yahoo.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o (NASDAQ:ARIA)
biz.yahoo.com - February 16 at 8:41 PM
News IconThe Must-Know Technicals As They Stand For ARIAD Pharmaceuticals, Inc. (ARIA) - NY Stock News (NASDAQ:ARIA)
nystocknews.com - February 16 at 3:40 PM
News IconThe Technical Case for and Against ARIAD Pharmaceuticals, Inc. (ARIA) - The USA Commerce (NASDAQ:ARIA)
theusacommerce.com - February 16 at 3:40 PM
finance.yahoo.com logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. - Yahoo Finance (NASDAQ:ARIA)
finance.yahoo.com - February 16 at 3:40 PM
finance.yahoo.com logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA)
au.finance.yahoo.com - February 16 at 3:40 PM
News IconEquity Perception: Analyst's Indicator Review for Hecla Mining Company (HL), ARIAD Pharmaceuticals, Inc. (ARIA) - The USA Commerce (NASDAQ:ARIA)
www.theusacommerce.com - February 16 at 8:31 AM
News IconARIAD Pharmaceuticals, Inc. (ARIA): What's the Story? - StockNewsJournal (NASDAQ:ARIA)
stocknewsjournal.com - February 16 at 8:31 AM
News IconBuy or Sell? What Analysts Recommends: NRG Energy, Inc. (NRG), ARIAD Pharmaceuticals, Inc. (ARIA) - StockNewsJournal (NASDAQ:ARIA)
stocknewsjournal.com - February 16 at 8:31 AM
News IconTraders Secrets on CF Industries Holdings, Inc. (CF), ARIAD Pharmaceuticals, Inc. (ARIA) (NASDAQ:ARIA)
hypelee.com - February 15 at 2:16 AM
News IconAriad Pharmaceuticals Inc. (NASDAQ:ARIA) now has Insider Ownership of 0.3% (NASDAQ:ARIA)
latribunadecanarias.com - February 14 at 9:16 PM
News IconARIAD Pharmaceuticals, Inc. (ARIA) Analyst Opinion And Outlook (NASDAQ:ARIA)
xboxonezone.com - February 14 at 9:16 PM
News IconWhat the Charts are Saying About ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Baldwin Journal (NASDAQ:ARIA)
baldwinjournal.com - February 14 at 4:13 PM
News IconARIAD Pharmaceuticals, Inc. (ARIA) : Checking the Chart - The USA Commerce (NASDAQ:ARIA)
theusacommerce.com - February 14 at 4:13 PM
News IconSunoco Logistics Partners LP (SXL), ARIAD Pharmaceuticals, Inc. (ARIA) Stock Eyes Ahead of Earnings - The USA Commerce (NASDAQ:ARIA)
www.theusacommerce.com - February 13 at 9:06 PM
News IconDrilling Down Into the Charts for ARIAD Pharmaceuticals, Inc. (ARIA) - The USA Commerce (NASDAQ:ARIA)
theusacommerce.com - February 11 at 3:37 PM
News IconRevenue Approximations Analysis: ARIAD Pharmaceuticals, Inc. (ARIA), Rowan Companies plc (RDC) - StockNewsJournal (NASDAQ:ARIA)
stocknewsjournal.com - February 11 at 3:37 PM
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:ARIA)
www.thestockobserver.com - February 11 at 3:37 PM
News IconTraders Watch List – JPMorgan Chase & Co. (NYSE:JPM), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - Financial Breaking News (NASDAQ:ARIA)
wsbreakingnews.com - February 9 at 3:45 PM
News IconWhat Analysts are Predicting For Opko Health, Inc. (OPK), ARIAD Pharmaceuticals, Inc. (ARIA)? - The USA Commerce (NASDAQ:ARIA)
theusacommerce.com - February 9 at 3:45 PM
News IconInvestor Watch: Zooming in on the Levels for ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Baldwin Journal (NASDAQ:ARIA)
baldwinjournal.com - February 9 at 1:55 AM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ARIA)
us.rd.yahoo.com - February 8 at 8:53 PM
News IconInvestor Corner: Checking in on Shares of Ariad Pharmaceuticals Inc. (ARIA) - Benton Bulletin (NASDAQ:ARIA)
bentonbulletin.com - February 8 at 3:53 PM
istreetwire.com logoTrader Alert: Naked Brand Group Inc. (NAKD), ARIAD Pharmaceuticals, Inc. (ARIA), Under Armour, Inc. (UA) - iStreetWire (NASDAQ:ARIA)
istreetwire.com - February 8 at 3:53 PM
News IconAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) Awaits The Approval Of Its Brigatinib (NASDAQ:ARIA)
www.financialstrend.com - February 7 at 4:31 PM
finance.yahoo.com logoARIAD Files for EU Approval of Lung Cancer Drug Brigatinib (NASDAQ:ARIA)
finance.yahoo.com - February 7 at 4:31 PM
investopedia.com logoAriad Submits Brigatinib Marketing Application (ARIA) (NASDAQ:ARIA)
www.investopedia.com - February 7 at 1:44 AM
rttnews.com logoARIAD Pharma Reports Submission Of MAA For Brigatinib To EMA (NASDAQ:ARIA)
www.rttnews.com - February 7 at 1:44 AM
News IconGranite Point Capital Management LP Increases Stake in ARIAD Pharmaceuticals, Inc. (ARIA) (NASDAQ:ARIA)
mlbinjurynews.com - February 7 at 1:44 AM
smarteranalyst.com logoStock Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Announces Submission of MAA for Brigatinib to the EMA (NASDAQ:ARIA)
www.smarteranalyst.com - February 7 at 1:44 AM
News IconThe ARIAD Pharmaceuticals, Inc. (ARIA) Short Interest Down 25.8% in January (NASDAQ:ARIA)
prensariotiretail.com - February 7 at 1:44 AM
us.rd.yahoo.com logo7:35 am Ariad Pharm submits a MMA for its ALK inhbiter, brigatinib, to the EMA (NASDAQ:ARIA)
us.rd.yahoo.com - February 7 at 1:44 AM
us.rd.yahoo.com logoARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency (NASDAQ:ARIA)
us.rd.yahoo.com - February 7 at 1:44 AM
us.rd.yahoo.com logoAriad Submits Marketing Application to EU Agency (NASDAQ:ARIA)
us.rd.yahoo.com - February 7 at 1:44 AM
News IconLooking at the Tea Leaves for ARIAD Pharmaceuticals, Inc. (ARIA) - The USA Commerce (NASDAQ:ARIA)
www.theusacommerce.com - February 6 at 3:42 PM
News IconARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Bearish Target At $24 - Stock Observer (NASDAQ:ARIA)
www.thestockobserver.com - February 6 at 3:42 PM
fool.com logoWhy Ariad Pharmaceuticals Stock Nearly Doubled in January - Motley Fool (NASDAQ:ARIA)
www.fool.com - February 6 at 3:42 PM
fool.com logoWhy Ariad Pharmaceuticals Stock Nearly Doubled in January (NASDAQ:ARIA)
www.fool.com - February 6 at 1:30 PM

Social

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?

10 brokerages have issued 12-month target prices for Ariad Pharmaceuticals' stock. Their predictions range from $7.00 to $24.00. On average, they anticipate Ariad Pharmaceuticals' stock price to reach $16.54 in the next year.

When will Ariad Pharmaceuticals announce their earnings?

Ariad Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Who owns Ariad Pharmaceuticals stock?

Ariad Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (9.33%), BlackRock, Inc (7.70%), Takeda Pharmaceutical Company Limited (6.80%), Sarissa Capital Management LP (6.62%), State Street Corp (4.05%) and Putnam Investments LLC (0.00%). Company insiders that own Ariad Pharmaceuticals stock include Athanese Lavidas, Daniel M Bollag, David L Berstein, Edward M Fitzgerald, Frank Haluska, Hugh M Cole, Maria E Cantor, Martin J Duvall, Massimo Radaelli, Paris Panayiotopoulos and Timothy P Clackson.

Who sold Ariad Pharmaceuticals stock? Who is selling Ariad Pharmaceuticals stock?

Ariad Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management, Royce & Associates LP, Opaleye Management Inc., Guggenheim Capital LLC, Commerzbank Aktiengesellschaft FI, National Planning Corp and State Board of Administration of Florida Retirement System. Company insiders that have sold Ariad Pharmaceuticals stock in the last year include Athanese Lavidas, Daniel M Bollag, David L Berstein, Edward M Fitzgerald, Frank Haluska, Hugh M Cole, Maria E Cantor, Martin J Duvall, Massimo Radaelli and Timothy P Clackson.

Who bought Ariad Pharmaceuticals stock? Who is buying Ariad Pharmaceuticals stock?

Ariad Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, FMR LLC, Putnam Investments LLC, Two Sigma Investments LP, A.R.T. Advisors LLC, State Street Corp, Advisory Research Inc. and Palo Alto Investors LLC.

How do I buy Ariad Pharmaceuticals stock?

Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ariad Pharmaceuticals stock cost?

One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.

Ariad Pharmaceuticals (NASDAQ:ARIA) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Earnings History Chart

Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Dividend History Chart

Dividend Payments by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Last Updated on 2/27/2017 by MarketBeat.com Staff